US recommends ‘pause’ to Johnson & Johnson jab rollout over blood clot fears

The US Food and Drug Administration has recommended a “pause” to the rollout of the Johnson & Johnson COVID vaccine so it can investigate reports of blood clots.

Officials say they are looking into six reported cases “of a rare & severe type of blood clot in individuals after receiving the vaccine”.

“Right now, these adverse events appear to be extremely rare,” the FDA said in a statement on Twitter.

It said until the cases had been assessed for their potential significance, “we are recommending this pause”.

“This is important to ensure that the health care provider community is aware of the potential for these adverse events and can plan due to the unique treatment required with this type of blood clot,” it added.

Articles You May Like

Murders of two 16-year-old boys in London linked as victims named
Sources: Freeze leaves Liberty, takes Auburn job
Quick Charge Podcast: November 28, 2022
Sunak’s speech shows cosy UK-China ties since Cameron’s pint with Xi are ‘beer today, gone tomorrow’
‘Momentous and historic’: New Alzheimer’s drug slows memory decline